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Abstract
Background: Despite an increasing awareness of the importance of innate immunity, the roles of natural killer (NK) cells in
transplant rejection and antiviral and cancer immunity during immunosuppression have not been clearly defined.
Methods: To address this issue we have developed a quantitative assay of NK cell function that can be used on clinical
samples and have studied the influence of immunosuppression on NK cell function. NK cell degranulation and intracellular
interferon (IFN)-c production were determined by flow cytometry of peripheral blood samples.
Results: Overnight ex vivo treatment of peripheral blood cells from healthy controls with ciclosporin or tacrolimus inhibited
NK cell degranulation and IFN-c production in a dose-dependent manner. A similar impairment of function was seen in NK
cells from patients treated in vivo with calcineurin inhibitors. In the early post-transplant period, there was a variable
reduction of NK cell counts after treatment with alemtuzumab and basiliximab.
Conclusions: The functional inhibition of NK cells in early transplant patients coincides with the period of maximum susceptibility
to viral infections. The ability to assay NK cell function in clinical samples allows assessment of the impact of immunosuppression
on these effector cells. This information may be helpful in guiding the titration of immunosuppression in the clinical setting.
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Introduction
Natural killer (NK) cells have potent effector functions and play
a key role in a range of immune responses, including those against
pathogens and cancers [1]; however, their role in transplantation
and response to transplant immunosuppression are not clearly
defined. NK cells provide innate immunity against abnormal cells,
where their activation depends on the integration of signals arising
from activating and inhibitory receptors on their cell surface [2].
The inhibitory receptors include the CD94/NKG2A/B heterodi-
mers, which we identified as receptors for human leukocyte
antigen (HLA)-E, and killer inhibitory receptors (KIR) which
interact with major histocompatibility complex (MHC) class I
molecules [3,4,5]. Activating receptors include NKG2D, which
interacts with a range of ligands including the highly polymorphic
MICA and MICB molecules, the natural cytotoxicity receptors
such as NKp46 and the KIR-like receptors, whose ligand
repertoires are not fully characterized, but include HLA molecules
[6,7,8]. An important feature of the NK cellular immune response
is that NK cells do not require prior sensitisation in order to exert
their effector function [1].
NK cells have two key effector functions, which are the
cytotoxic lysis of target cells and the release of inflammatory
cytokines that amplify the immune response, including interferon
(IFN)-c [1]. Around 90% of human peripheral blood NK cells are
characterized by a CD56
dim phenotype and display a high level of
cytotoxicity, while the remaining 10% are CD56
bright and display
greater cytokine secretion [9,10]. The subsets are believed to
represent sequential stages of maturation, in which the cytokine-
secreting CD56
bright cells give rise to more differentiated CD56
dim
killer cells [9].
NK cells are important in the early stages of viral infections and
NK cell deficiency predisposes to virus infections, in particular from
herpes viruses [11,12]. The role of NK cells in virus infection is
especially important when adaptive immunity is not fully active and
thisisanalogoustothesituationwithtransplantimmunosuppression
[11]. Human NK cells can kill virus-infected cells, including those
infected with cytomegalovirus, and cytomegalovirus encodes
molecules that help it to evade NK cells [1,13]. Ligands for human
NKG2D are elevated on cytomegalovirus-infected cells and this
receptor has been implicated in protection from cytomegalovirus
infection in human transplant recipients [14].
It has been reported that human NK cells can mediate rejection of
both allogeneic bone marrow and xenogeneic solid organ grafts
[15,16,17,18,19]. Moreover, expression of the NK cell activating
receptor NKG2D is increased with acute and chronic nephropathy
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and chronic transplant rejection [20]. Alloreactivity of NK cells can
also promote allograft tolerance in animal models [21,22,23]. Despite
the potential importance of NKcells in the contextof transplantation,
the impact of immunosuppressive strategies on NK cell numbers and
functions is poorly understood. A number of in vitro studies of the
actions of ciclosporin and tacrolimus on NK cell functions have
produced contradictory observations ranging from inhibition to
stimulation [24,25,26,27,28,29].
In this study we show that NK cell function and numbers are
reduced in transplant recipients, particularly at early time-points
when there is the highest susceptibility to opportunistic viral
infections. Accurate and simple assessment of NK cell function will
be useful in developing algorithms to help clinicians to decide on
the correct level of immunosuppression and to identify patients
with the highest risk of infective complications.
Results
Refinement and validation of an assay of NK cell function
To measure NK cell function ex vivo, we first developed an assay
of cytotoxic degranulation and cytokine production that was
sensitive and reproducible using peripheral blood samples. Killing
of target cells by NK cells results in cytotoxic degranulation with
exposure of the inner lysosomal membrane protein CD107a at the
NK cell surface, which can be detected by flow cytometry.
Cytokine secretion by NK cells can be assessed simultaneously by
flow cytometric evaluation of IFN-c production. To measure these
functions we exposed NK cells to known targets, which were either
HLA class I-deficient Daudi cells transfected with MICA, a ligand
for the activating receptor NKG2D (D860 cells), or untransfected
K562 cells. Overnight rested peripheral blood mononuclear cells
(PBMCs) (2.5610
5/well) were incubated in the presence or
absence of target cells (1.25610
6/well). Following the incubation
period, the cells were harvested, washed and stained with anti-
human CD3, CD56 and CD16 antibodies for flow cytometry. For
intracellular IFN-c detection, cells were permeabilized and stained
for IFN-c. NK cells were identified by gating on the lymphocyte
population and then on CD3
2 CD56
+ population. NK cell
degranulation was expressed as the percentage of NK cells that
were CD107a
+ and cytokine secretion was expressed as the
percentage of NK cells that were IFN-c
+.
Pilot studies of the assay using NK cells from healthy controls
showed that there was a time-dependent increase in NK cell
degranulation in response to the target cells with a near-maximal
response seen at 6 hours (Figure 1A). Further experiments showed
that responses were similar at 6 and 12 hours when both
degranulation and intracellular IFN-c production were assessed
(data not shown); therefore the 6 hour incubation was used in
future studies. We were also able to show that the proportion of
NK cells that degranulated was not increased by increasing the
number of target cells beyond an effector:target (E:T) cell ratios of
1:5 (Figure 1B). The term ‘effector’ here refers to the total number
of peripheral blood mononuclear cells added to the assay, but only
the NK cells in this population were assayed. The flow cytometric
assay excludes the analysis of CD3
+ cells, but there was no
significant degranulation of CD3
+ cells in the presence of K562 or
D860 target cells (0.1360.003% and 0.4360.02% respectively)
and negligible change in the proportion of CD3
+ cells secreting
IFN-c (0.00360.002% vs. 0.0260.002%). There was little
difference in the efficiency of D860 and K562 target cells, so
K562 cells were used in subsequent experiments. On the basis of
Figure 1. Development of an assay of NK cell function. (A) NK cell degranulation over time during incubation with different target cell lines at
an effector:target ratio of 1:5. The term ‘effector’ refers to the total number of peripheral blood mononuclear cells in the assay. (B) NK cell
degranulation after 6 hr at effector:target ratios ranging from 5:1 to 1:40. (C and D). Reproducibility of the NK cell assay on different samples taken
from individual healthy controls over several weeks (1–6) with a minimum interval of two weeks (individual circles). Closed and open circles on the
left and right of each panel indicate values obtained when cells were incubated overnight prior to the assay in medium alone or medium plus IL-2
respectively. The data demonstrate the extent to which the assay is reproducible over time within an individual using a 6 hour incubation with K562
target cells and a 1:5 effector:target ratio. Error bars represent standard deviations in all graphs in this figure.
doi:10.1371/journal.pone.0013294.g001
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five-fold excess of target cells and incubation period of 6 hours.
When absolute NK cell numbers were determined, no correlation
was found between the ratio of NK:target cells in the assay results
for 27 individuals (Figure S1); this ratio was generally of the order
of 1:100, with the smallest excess of target cells being a ratio of
1:53. With an E:T ratio of 1:5 and a 6 hour incubation with K562
cells, the test was sensitive and reproducible. The test remained
reproducible for different individuals tested at different times over
a period of several weeks (Figure 1C and 1D), with a mean
coefficient of variation of 14.1% for degranulation and 28.5% for
interferon gamma production. This is not the coefficient of
variation of the assay itself, but rather of the assay result over time
in any given individual. Overnight pre-activation of the NK cells
with interleukin-2 (IL-2) increased the level of degranulation and
the generation of IFN-c, without altering the reproducibility of the
assay (Figure 1C and 1D).
Calcineurin inhibitors reduce NK cell degranulation and
IFN-c production in vitro
Since the calcineurin inhibitors ciclosporin and tacrolimus are
the mainstay of most immunosuppression regimens in renal
transplantation, we studied their effects on NK cell function using
this assay. Overnight treatment of cells from healthy donors with
ciclosporin or tacrolimus caused a dose-dependent inhibition of
NK cell degranulation and IFN-c production in response to target
cells (Figure 2A and 2B). A strong statistically significant inhibitory
trend was seen with both drugs on degranulation and IFN-c
production (Tables S1 and S2.) At therapeutic trough levels of
tacrolimus (6–20 nM or 5–15 ng/ml) and ciclosporin (60–250 nM
or 75–300 ng/ml) there was a greater than 20% reduction in
degranulation and a greater than 90% reduction in IFN-c
production. More substantial changes were seen in the range
corresponding to the peak levels that can arise following
therapeutic dosing with tacrolimus (40–90 nM or 30–70 ng/ml)
or ciclosporin (800–1200 nM or 1000–1500 ng/ml). Overnight
treatment of the NK cells with IL-2 increased the number of cells
that degranulated in response to targets, but there was still a strong
statistically significant inhibition seen with both drugs on
degranulation and IFN-c production (Figure 2A). IL-2 also
increased IFN-c production at low levels of ciclosporin and
tacrolimus, but did not reverse the profound inhibition seen even
at drug levels corresponding to therapeutic trough levels
(Figure 2B). There was no significant change in NK cell numbers
with either treatment. These data indicate that NK cell function is
likely to be significantly impaired at therapeutic levels of
ciclosporin and tacrolimus.
Loss of NK cell function in the early post transplant
period
To assess NK cell function in renal transplant patients we
compared cells from early (,28 weeks) and late (.4 years)
transplant recipients with healthy controls. A cut off of 4 years was
used to ensure a wide separation between early and late patients.
When NK cells were incubated overnight with targets in medium,
no significant differences were seen between the different groups in
IFN-c production or cytotoxic degranulation (Figure 3A left panel
and Figure 3B left panel). In the light of our earlier experiments,
we considered the possibility that the absence of an effect in these
circumstances could be due to the removal of calcineurin
Figure 2. Ex vivo administration of ciclosporin or tacrolimus inhibits NK cell function. (A) PBMCs from healthy subjects (n=4–8 for each
data point) were incubated separately overnight with different concentrations of ciclosporin or tacrolimus with (open circles) or without (black
circles) IL-2. NK cell degranulation was assessed the following day by incubation with K562 target cells for 6 hrs at a 1:5 E:T ratio. The values for
CD107a
+ NK cells are expressed as a percentage of the basal level of CD107a
+ surface expression in the assay for that individual in the absence of
both the drugs and IL-2. The shaded area represents the range of drug levels encountered in clinical practice with renal transplantation. (B) IFN-c
production was evaluated by flow cytometry in the same assays as used in (A). The values of IFN-c
+ NK cells are expressed as a percentage of the
basal level of IFN-c
+ expression for that individual in the assay in the absence of both the drugs and IL-2. Values are mean 6 standard deviation. The
data demonstrate that both ciclosporin and tacrolimus impair NK cell degranulation and IFN-c production at levels corresponding to those used in
clinical practice. In both A and B there was as strongly significant trend of inhibition (see Tables S1 and S2 for statistical analysis.).
doi:10.1371/journal.pone.0013294.g002
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are given in Table S3). When PBMCs were incubated overnight in
cultures to which the patient’s own plasma had been added back,
both IFN-c production and NK cell degranulation were lower in
early transplant recipients compared to normal controls (Figure 3A
right panel and Figure 3B right panel). Late transplant patients
had lower values for both NK degranulation and IFN-c
production than healthy controls, but these changes did not reach
statistical significance. When the assays were performed with
PBMCs which had been rested in autologous plasma with IL-2,
there was an even more marked difference seen in NK cell
degranulation between healthy controls and early transplant
patients, consistent with a therapy-induced blockade of the effects
of IL-2 (54.363.1 vs 33.164.6%, p,0.05 with ANOVA and
Dunnett’s test) caused by the drug in the plasma. The addition of
IL-2 to cells rested in medium did not increase the discrimination
of the assay between the different groups suggesting that the effects
seen with plasma are due to drug-induced IL-2 blockade (data not
shown). Contingency table analysis using Chi-square testing and
Fisher’s exact test did not demonstrate any significant difference
between the early and late groups in terms of their use of other
immunosuppressive drugs (mycophenolate, azathioprine and
prednisolone).
Variation in NK cell numbers in early and late kidney
transplant patients
To assess the effects of immunosuppression on the development
and survival of NK cells, as well as function, we measured absolute
numbers of NK cells in blood from patients and controls (Figure 4).
For these purposes, early transplant recipients were further
subdivided into patients who had received alemtuzumab (anti-
CD52) or basiliximab (anti-CD25) therapy because alemtuzumab is
known to cause T cell, B cell and dendritic cell depletion and we
wished to examine the effects on NK cells. As Figure 4 illustrates,
this was informative as there are clearly effects of alemtuzumab on
NK cell numbers. No late transplant patients were on alemtuzumab
or basiliximab. Compared to healthy controls (1.8060.15610
6
cells/ml), total lymphocyte counts were significantly lower in
alemtuzumab-treated early transplant patients (0.1660.02610
6
cells/ml), non-significantly lower in basiliximab-treated early
transplant patients (1.1760.24610
6 cells/ml), but preserved in late
transplant patients (1.7460.22610
6 cells/ml) (Figure 4A). CD3
+ T
lymphocyte counts were 90-fold lower in alemtuzumab-treated
early transplant patients compared to healthy controls (0.026
0.01610
6 cells/ml vs 1.8060.15610
6 cells/ml) and non-signifi-
cantly lower in basiliximab-treated early transplant patients
(0.9360.21610
6 cells/ml) and late transplant patients (1.296
0.17610
6 cells/ml) (Figure 4B). In contrast, absolute NK cell
counts were only 4-fold lower in alemtuzumab-treated early
transplant patients compared to healthy controls (0.0460.01610
6
cells/ml vs 0.1760.02610
6 cells/ml) (Figure 4C). Late transplant
patients had relative preservation of NK cells (0.13610
660.03610
6
cells/ml). The proportion of NK cells that were CD56
dim was non-
significantly lower in the alemtuzumab group compared to the
healthy controls (Figure 4D). NK cell counts and the ratio of
CD56
dim to CD56
bright NK cells were significantly lower in late
transplant patients treated with ciclosporin compared to those
treated with tacrolimus) (Table S4). Ciclosporin treatment was also
associated with a significant reduction in both NK cell degranula-
tion (29.364.0% vs 43.264.1%) and IFN-c production (6.461.2%
vs. 14.263.1%) compared to tacrolimus treatment in this group
(Table S4).
Figure 3. NK cell function is altered in renal transplant patients. (A) PBMCs from healthy controls, early transplant patients and late
transplant patients were isolated and incubated overnight in culture media or the subject’s plasma. NK cell degranulation was assayed the following
day by incubation with K562 cells for 6 hrs at a 1:5 E:T ratio. (B) IFN-c production was evaluated in the same groups as used in (A). Values are
individual patients and bars represent means. The data show that when cells are maintained in autologous plasma, NK cells from early transplant
patients have impaired NK cell degranulation and IFN-c production. (* p,0.05 with ANOVA followed by Dunnett’s test).
doi:10.1371/journal.pone.0013294.g003
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In this study we describe the development of a cytometric assay
that allows rapid assessment of the two key components of NK cell
effector function - cytotoxicity and cytokine secretion. This builds
on the ability to detect intracellular IFN-c production and the
repeated demonstration that expression of CD107a correlates
closely with NK cell-induced cytotoxic lysis of target cells in Cr
51-
release assays [30,31,32]. The flow cytometric assays are robust,
reproducible, suitable for a high throughput of clinical samples
and can be performed during normal working hours. A wide range
of clinical assays exists for B and T cell function and this study
addresses the important need for a simple assay of NK cell
function that can be used in a variety of disease settings.
An important aspect of the assay is that it does not require pre-
separation of individual nucleated blood cell subsets and can be
done directly on mixed populations of peripheral blood mononu-
clear cells after simple counting. The flow cytometric gating used
ensures that the assay reports on the proportion of NK cells which
have degranulated or are secreting interferon gamma. Unlike a
chromium release assay where the measured output is the
destruction of the target, this assay uses as its readout the status
of the NK cell itself. The output depends on the probability that a
given NK cell will encounter a target and then on the probability
that this encounter will result in NK effector function. The ratio of
1:5 for total peripheral blood cells: target cells was used so that
there is a very large excess of target cells compared to NK cells,
which form only a small proportion of the total peripheral blood
mononuclear cell count. This ratio of NK cells to target cells is of
the order of 1:100 and as Figure 1B indicates, this excess is such
that there is no further increase in measured effector function with
an even higher proportion of target cells in the assay. This
indicates that the number of target cells used in the assay is not
limiting, presumably because with such an excess of target cells,
the probability of an encounter between an NK cell and a target
cell is not increased further by the presence of more target cells.
Because the number of target cells is not limiting, it is possible to
use the assay to assess the probability that an encounter results in
NK effector function. As the assay measures the percentage of the
NK cells which are activated, this result is not dependent on the
absolute number of NK cells in the assay. The output of the assay
is relatively stable in individuals over time as indicated by the
results in Figure 1C and 1D and the coefficients of variation.
To validate the assays in the context of immunosuppression, we
have measured the effects of the calcineurin inhibitors ciclosporin
and tacrolimus on NK cell function in vitro. Our data demonstrate
that both drugs produced dose-dependent inhibition of NK cell
degranulation and IFN-c production in vitro. These inhibitory
effects were highly statistically significant with strong correlation
coefficients. This resolves any uncertainty about the effects of these
drugs on human NK cell function. Our findings confirm studies
reporting an inhibition of NK cell degranulation with ciclosporin
[26,27,33] and tacrolimus [33]. Although some reports have
suggested that ciclosporin had no effect [24,25,34] or slightly
increased NK cell activity [28], and that tacrolimus had no effect
on NK cell activity [24,27], we believe these inconsistencies may
reflect species-specific differences or the removal of the drug by
washing during or prior to the assays [24]. Importantly, the
inhibition of NK cell function by ciclosporin is known to be
reversible [27] and our ex vivo samples required re-addition of
autologous plasma, which contained the drug at therapeutic levels,
in order to demonstrate difference between cells from patients
and healthy controls. The marked reduction in NK cell function
in early transplant patients may reflect the higher doses of
immunosuppressive drugs which are used in these patients
Figure 4. NK cells in peripheral blood cells of renal transplant patients. (A) Total lymphocyte counts, (B) CD3
+ lymphocyte counts, (C)N K
cell counts and (D) CD3
2, CD16
+, CD56
dim : CD56
bright NK cell ratios in healthy controls, early transplant patients having received either alemtuzumab
or basiliximab, and late transplant patients. The data demonstrate that alemtuzumab treatment is associated with reduced total lymphocyte counts,
CD3
+ lymphocyte counts and NK cell counts. Values are individual patients and bars represent means. (* p,0.05 with ANOVA followed by Dunnett’s
test or Tukey’s test).
doi:10.1371/journal.pone.0013294.g004
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seen when the cells were rested in autologous plasma containing
the drug and IL-2. This is consistent with the immunosuppressive
drug in the early transplant patients’ plasma being responsible for
the inhibition of NK cell function. Whilst plasma clearly contains a
wide range of biologically active constituents, the evidence
indicates that it is likely to be the drug which is causing the effect
seen. Consistent with this interpretation, plasma from patients
recapitulates the effects seen with drug alone. Furthermore,
plasma from normal healthy donors had no effect on the assay
results and the addition of IL-2 to cells in medium alone did not
alter the discrimination of the assay suggesting that in the absence
of the drug IL-2 had similar effects on cells from both healthy
donor and transplant patients.
The plasma levels of both ciclosporin and tacrolimus depend on
the dose administered and the time between administration and
blood sampling. For clinical purposes, drug therapy is usually
monitored using the trough level measured before the next dose.
However, these are the lowest levels experienced by the patients’
immune cells and substantially higher peak levels can be seen
[35,36]. Furthermore, higher drug levels are used in heart, lung
and liver transplantation than in kidney transplantation. Our
results indicate that both ciclosporin and tacrolimus will have
significant NK cell suppressive effects when used as transplant
immunosuppression. There are likely to be many factors
influencing the appropriate level of transplant immunosuppression
including age, co-morbidity, HLA-matching, immunosuppressive
drug levels and the function of different immune cell subsets
including regulatory T cells, B cells and NK cells. It is likely that
the development of any clinical decision-support algorithm to fine
tune immunosuppression by altering dosing will have to assess
these and potentially other factors. However, the key requirements
at present are suitable assays to assess these different variables. We
believe that the assay that we have developed will be of great utility
for future studies to establish the value of monitoring NK cells
function following transplantation. The current study clearly
demonstrates that NK cell function is impaired following
transplantation and it will be important in future studies to
determine the clinical significance of this effect and the value of
monitoring it and of fine tuning immunosuppression to minimize
this inhibition of NK cell function.
Blood NK cells numbers vary widely in normal populations and
therefore we considered that it might be difficult to correlate these
changes with functional effects. However, our analysis provides
clear evidence that NK cell numbers are relatively preserved in
most patients. Alemtuzumab is a known T cell, B cell and
dendritic cell depleting antibody [37,38]. Alemtuzumab has been
previously reported to spare NK cells [39], marginally decrease
CD16
+ NK cell counts until 1–2 months after treatment [40,41],
or to deeply suppress NK cells for over 9 months after treatment
[42]. Our results demonstrate that compared to other lympho-
cytes, NK cells are relatively spared by alemtuzumab.
The role of NK cells in viral infection is well established and
they play a particular role in the early stages of infection before
adaptive immunity can be mobilized [11]. Human NK cell
deficiency is associated with severe herpes virus infection [12]. The
protection from herpes viruses which is mediated by NK cells is
especially relevant to transplantation, where the graft may bring
about new viral exposure, especially to cytomegalovirus and there
is simultaneous therapeutic suppression of adaptive immunity.
Our study indicates that at this critical time, there is also a
substantial measurable reduction in NK cell function. Clearly, the
optimisation of immunosuppression regimens may require atten-
tion to the effects on NK cell function, as excess use of the
immunosuppressive regimens that we have studied would lead to
profound defects in NK cell function with concomitant risks of
disease due to cytomegalovirus and other viruses. The assay that
we have developed is sensitive to these effects and can easily be
applied to clinical samples.
Natural killer cells play an important role in cancer immuno-
surveillance and the incidence of cancer is increased following
transplantation [43,44]. In the longer term, patients treated with
ciclosporin had lower NK cell counts and weaker NK cell
cytotoxic activity than late transplant patients treated with
tacrolimus. We also observed a lower CD56
dim:CD56
bright ratio
in ciclosporin-treated patients than in tacrolimus-treated patients.
Our observations are consistent with a previous study of renal
transplant recipients, which showed an early reduction in NK cell
numbers with both tacrolimus and ciclosporin with restoration of
numbers in the tacrolimus-treated group, but not in the
ciclosporin-treated group at one year post transplant [45].
Overall, our results indicate that NK cell numbers and function
are strongly influenced by standard immunosuppressive regimens.
This is an important finding and is likely to have important
consequences in both the early and late post-transplant periods,
when viral infections and tumorigenesis can occur. NK cell function
is not routinely monitored following transplantation, but our data
suggest that it will be important to evaluate NK function in the
development of algorithms for tailoring immunosuppression.
Materials and Methods
Ethics Statement
This study was approved by the local ethical review committee
(Mid and South Buckinghamshire Research Ethics committee; full
title: Immune function in autoimmunity and immunosuppression;
REC ref number: 08/H0607/50).
Patient recruitment and clinical samples
Transplant patients from the Oxford Transplant Unit (Oxford
Radcliffe Hospitals, Churchill Hospital, Oxford, U.K.) were
recruited to the study after giving written informed consent.
Healthy controls were also recruited. Late transplant recipients
(n=14) were defined as patients having undergone transplantation
at least 4 years prior to blood collection, and early transplant
recipients (n=15) as patients having undergone transplantation 4
to 28 weeks prior to blood collection. A 4 year cut off was chosen
to ensure that all late patients were substantially beyond the peri-
transplant period. Either ciclosporin or tacrolimus were used as a
maintenance treatment in all patients. Induction treatment
consisted of two intravenous injections of either 30 mg of
alemtuzumab (once post-organ reperfusion and once 24 hrs later),
or 20 mg of basiliximab (once before transplantation and once on
day 4 post transplantation). Alemtuzumab is a humanized
monoclonal antibody against CD52 and causes depletion of cells
expressing this antigen. Basiliximab is a humanized monoclonal
antibody against CD25 on T cells and blocks effective T cell
proliferation. Healthy control samples were obtained from
individuals who were well, with no known medical conditions,
no inflammatory or infectious conditions and who were not taking
any drugs nor had recently used alcohol or smoked. Up to 20 ml
of heparinized blood was obtained by venepuncture. When
required, this was diluted with twice the volume of phosphate
buffer saline (PBS) and centrifuged over 15 ml of Ficoll-Paque Plus
for 20 min at 700 g. Mononuclear cells were collected at the
interface and washed three times with PBS at 300 g for 10 min.
Unless indicated otherwise, the cells were incubated overnight at
37uC in 20 ml of RPMI 1640 medium (supplemented with 10%
NK Cells in Transplantation
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PBMCs were counted using a hemocytometer and plated as
indicated. For plasma isolation, heparinized blood was centrifuged
for 10 min at 300 g and the supernatant stored at 4uC.
Reagents and cell culture
L-glutamine, penicillin-streptomycin, RPMI 1640, brefeldin A,
ciclosporin, and tacrolimus were obtained from Sigma-Aldrich
(Poole, U.K.); PBS from HyClone (Cramlington, U.K.); FCS from
Biosera (Ringmer, U.K.); bovine serum albumin (BSA) from
Fisher-Scientific (Loughborough, U.K.); Ficoll-Paque Plus from
GE Healthcare (Piscataway, NJ); IL-2 from Peprotech Ltd (Rocky
Hill, NJ); GolgiStop, Cytofix/cytoperm, Permwash II buffer, anti-
human CD56-PE-Cy7 and anti-human CD16-PE mouse anti-
bodies from BD Biosciences (San Jose, CA); anti-human CD3-
APC-eFluor 780 and anti-human IFN-c-AlexaFluor 647 antibod-
ies from eBioscience (San Diego, CA); and anti-human CD107a-
AlexaFluor 488 from either eBioscience or BioLegend (San Diego,
CA). K562 cells were obtained from the American Type Culture
Collection and D860 cells were obtained by transfecting Daudi
cells with the NKG2D ligand MICA. Where indicated, PBMCs
were incubated with various concentrations of ciclosporin or
tacrolimus or with IL-2 (100 U/ml) overnight prior to and during
the CD107a/IFN-c assay.
CD107a (LAMP-1) and intracellular IFN-c assay
PBMCs were plated in 24-well plates with or without 2.5610
5
target cells in a 1 ml final volume of medium, plasma or serum,
then incubated, typically for 6 hours at 37uC. After 30 minutes,
0.7 ml GolgiStop (monensin) and anti-human CD107a-Alexa-
Fluor 488 antibody were added to each well. At 6 hours, cells
were washed once in 2 ml of PBS, 2% bovine serum albumin,
spun for 5 min at 300 g, then stained with anti-human CD3-
APC-eFluor780, anti-human CD56-PE-Cy7 and anti-human
CD16-PE antibodies for 30 min at room temperature. Cells
were washed once in 2 ml of PBS, 2% BSA and resuspended
in either 500 mlo fP B S ,2 %B S Ao r5 0 0 mlo fP B S ,2 %
paraformaldehyde.
The assayforintracellularIFN-c was performedinparallelwith a
few adaptations. After 30 minutes of incubation, the transport
inhibitor brefeldin A (0.3 mg/ml) was added to each well along with
GolgiStop. After surface staining for CD3, CD56 and CD16, the
cells were washed once in PBS, 2% BSA buffer, spun and
permeabilized with 100 ml of BD Cytofix/cytoperm buffer, for
20 min at room temperature. The cells were washed twice with
500 ml of BD Perm/Wash buffer II, spun and stained with anti-
human IFN-c-AlexaFluor647 antibody for 30 min at room
temperature. Cells were washed once in 2 ml of PBS, 2% BSA
and resuspended in 500 ml of PBS, 2% paraformaldehyde. NK cells
were identified by gating on CD3
2 CD56
+ CD16
+ lymphocytes.
Flow cytometry analysis and statistical analysis
Flow cytometry was performed on a BD FACSCanto machine
using the BD FACSDiva software. Flow cytometry data were
analyzed using the FlowJo 8.8.3 software (Tree Star, Inc., Ashland,
OR). Statistical analysis was performed using the Prism 5 software
(GraphPad Software, Inc. La Jolla, CA). Two-group comparisons
(fig. 1 and 2) were performed using unpaired two-tailed t-tests.
Three-group (fig. 3) and four-group (fig. 4) comparisons were done
using the one-way ANOVA followed, when significant, by the
Tukey’s mutiple comparison test or Dunnett’s multiple compar-
ison test. Trend analysis was performed using Spearman’s test.
Supporting Information
Table S1 Correlation analysis of CD107a data in Figure 2 using
Spearman’s test.
Found at: doi:10.1371/journal.pone.0013294.s001 (0.03 MB
DOC)
Table S2 Correlation analysis of IFN-c data in Figure 2 using
Spearman’s test.
Found at: doi:10.1371/journal.pone.0013294.s002 (0.03 MB
DOC)
Table S3 Drug levels in patient groups.
Found at: doi:10.1371/journal.pone.0013294.s003 (0.03 MB
DOC)
Table S4 Comparison of results for late transplant patients
taking ciclosporin and tacrolimus.
Found at: doi:10.1371/journal.pone.0013294.s004 (0.03 MB
DOC)
Figure S1 NK cell:Target cell ratio. No correlation was seen
between absolute NK cell:Target cell ratio and assay outcome.
The outcome of degranulation assays for 27 individuals were
analyzed using Pearson’s and Spearman’s tests for correlation and
no significant correlation was seen between the assay outcome and
the absolute NK cell count.
Found at: doi:10.1371/journal.pone.0013294.s005 (0.06 MB
DOC)
Acknowledgments
We are grateful to the staff and patients of the Oxford Kidney unit and
healthy volunteers who have made this study possible.
Author Contributions
Conceived and designed the experiments: OM AC PDM RC CAO.
Performed the experiments: OM SB SB CC. Analyzed the data: OM SB
AC PDM RC CAO. Contributed reagents/materials/analysis tools: AC
SB CC CAO. Wrote the paper: OM RC CAO.
References
1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of
natural killer cells. Nat Immunol 9: 503–510.
2. Lanier LL (2008) Up on the tightrope: natural killer cell activation and
inhibition. Nat Immunol 9: 495–502.
3. Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, et al.
(1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Nature 391: 795–799.
4. O’Callaghan CA, Bell JI (1998) Structure and function of the human MHC class Ib
molecules HLA-E, HLA-F and HLA-G. Immunological Reviews 163: 129–138.
5. Norman PJ, Parham P (2005) Complex interactions: the immunogenetics of
human leukocyte antigen and killer cell immunoglobulin-like receptors. Semin
Hematol 42: 65–75.
6. Mistry AR, O’Callaghan CA (2007) Regulation of ligands for the activating
receptor NKG2D. Immunology 121: 439–447.
7. O’Callaghan CA, Cerwenka A, Willcox BE, Lanier LL, Bjorkman PJ (2001)
Molecular competition for NKG2D: H60 and RAE1 compete unequally for
NKG2D with dominance of H60. Immunity 15: 201–211.
8. Arnon TI, Markel G, Mandelboim O (2006) Tumor and viral recognition by
natural killer cells receptors. Semin Cancer Biol 16: 348–358.
9. Caligiuri MA (2008) Human natural killer cells. Blood 112: 461–469.
10. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, et al. (2001) CD56bright
cells differ in their KIR repertoire and cytotoxic features from CD56dim NK
cells. Eur J Immunol 31: 3121–3127.
11. Welsh RM, Jr., Zinkernagel RM (1977) Heterospecific cytotoxic cell activity
induced during the first three days of acute lymphocytic choriomeningitis virus
infection in mice. Nature 268: 646–648.
12. Biron CA, Byron KS, Sullivan JL (1989) Severe herpesvirus infections in an
adolescent without natural killer cells. N Engl J Med 320: 1731–1735.
NK Cells in Transplantation
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e1329413. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, et al. (2001)
ULBPs, Novel MHC class I related moelcules, bind to CMV glycoprotein UL16
and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:
123–133.
14. Hadaya K, de Rham C, Bandelier C, Bandelier C, Ferrari-Lacraz S, et al. (2008)
Natural killer cell receptor repertoire and their ligands, and the risk of CMV
infection after kidney transplantation. Am J Transplant 8: 2674–2683.
15. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched
hematopoietic transplants. Science 295: 2097–2100.
16. Auchincloss H, Jr., Sachs DH (1998) Xenogeneic transplantation. Annu Rev
Immunol 16: 433–470.
17. Manilay JO, Sykes M (1998) Natural killer cells and their role in graft rejection.
Curr Opin Immunol 10: 532–538.
18. Blancho G, Buzelin F, Dantal J, Hourmant M, Cantarovich D, et al. (1992)
Evidence that early acute renal failure may be mediated by CD3- CD16+ cells in
a kidney graft recipient with large granular lymphocyte proliferation.
Transplantation 53: 1242–1247.
19. Kroemer A, Xiao X, Degauque N, Edtinger K, Wei H, et al. (2008) The innate
NK cells, allograft rejection, and a key role for IL-15. J Immunol 180:
7818–7826.
20. Seiler M, Brabcova I, Viklicky O, Hribova P, Rosenberger C, et al. (2007)
Heightened expression of the cytotoxicity receptor NKG2D correlates with
acute and chronic nephropathy after kidney transplantation. Am J Transplant 7:
423–433.
21. Beilke JN, Kuhl NR, Van Kaer L, Gill RG (2005) NK cells promote islet
allograft tolerance via a perforin-dependent mechanism. Nat Med 11:
1059–1065.
22. Laffont S, Seillet C, Ortaldo J, Coudert JD, Guery JC (2008) Natural killer cells
recruited into lymph nodes inhibit alloreactive T-cell activation through
perforin-mediated killing of donor allogeneic dendritic cells. Blood 112:
661–671.
23. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC (2006) NK cells promote transplant
tolerance by killing donor antigen-presenting cells. J Exp Med 203: 1851–1858.
24. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM (2008) Rapamycin, but
not cyclosporine or FK506, alters natural killer cell function. Transplantation 85:
145–149.
25. Shao-Hsien C, Lang I, Gunn H, Lydyard P (1983) Effect of in vitro cyclosporin.
A treatment on human natural and antibody-dependent cell-mediated
cytotoxicity. Transplantation 35: 127–129.
26. Introna M, Allavena P, Spreafico F, Mantovani A (1981) Inhibition of human
natural killer activity by cyclosporin A. Transplantation 31: 113–116.
27. Wasik M, Gorski A, Stepien-Sopniewska B, Lagodzinski Z (1991) Effect of
FK506 versus cyclosporine on human natural and antibody-dependent
cytotoxicity reactions in vitro. Transplantation 51: 268–270.
28. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, et al. (2007) The
unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural
killer cell subpopulations. Blood 110: 1530–1539.
29. Petersson E, Qi Z, Ekberg H, Ostraat O, Dohlsten M, et al. (1997) Activation of
alloreactive natural killer cells is resistant to cyclosporine. Transplantation 63:
1138–1144.
30. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the
identification of natural killer cell activity. J Immunol Methods 294: 15–22.
31. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009) Relationship
between CD107a expression and cytotoxic activity. Cell Immunol 254: 149–154.
32. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, et al.
(2005) CD56dimCD16neg cells are responsible for natural cytotoxicity against
tumor targets. Leukemia 19: 835–840.
33. Pores-Fernando AT, Gaur S, Doyon MY, Zweifach A (2009) Calcineurin-
dependent lytic granule exocytosis in NK-92 natural killer cells. Cell Immunol
254: 105–109.
34. Lin SJ, Kuo ML (2008) Effect of cyclosporin A on interleukin-15-activated
umbilical cord blood natural killer cell function. Cytotherapy 10: 397–405.
35. Kimikawa M, Kamoya K, Toma H, Teraoka S (2001) Effective oral
administration of tacrolimus in renal transplant recipients. Clin Transplant 15:
324–329.
36. Mahalati K, Lawen J, Kiberd B, Belitsky P (2000) Is 3-hour cyclosporine blood
level superior to trough level in early post-renal transplantation period? J Urol
163: 37–41.
37. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human
antibodies for therapy. Nature 332: 323–327.
38. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, et al. (2002) Peripheral
blood but not tissue dendritic cells express CD52 and are depleted by treatment
with alemtuzumab. Blood 100: 1715–1720.
39. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, et al. (1992)
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:
748–752.
40. Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, et al. (1997)
Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma
patients treated with Campath-1H (anti-CD52). Eur J Haematol 58: 5–13.
41. Brett S, Baxter G, Cooper H, Johnston JM, Tite J, et al. (1996) Repopulation of
blood lymphocyte sub-populations in rheumatoid arthritis patients treated with
the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology
88: 13–19.
42. Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, et al.
(2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-
CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for
B-cell chronic lymphocytic leukaemia. Leukemia 18: 484–490.
43. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of
cancers in people with HIV/AIDS compared with immunosuppressed
transplant recipients: a meta-analysis. Lancet 370: 59–67.
44. van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, McDonald SP,
et al. (2010) Effect of reduced immunosuppression after kidney transplant failure
on risk of cancer: population based retrospective cohort study. BMJ 340: c570.
45. Vacher-Coponat H, Brunet C, Moal V, Loundou A, Bonnet E, et al. (2006)
Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte recon-
stitution one year after kidney transplant by reference to cyclosporine/
azathioprine. Transplantation 82: 558–566.
NK Cells in Transplantation
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13294